CD8A and neoplasm: Figure 6a shows infiltration of more CD4+ T cells in the tumours treated with PTX/PEG2k-Fmoc-NLG(L) compared with control or Taxol groups (P<0.05). There were also more CD8+ T cells in the tumours treated with PTX/PEG2k-Fmoc-NLG(L) compared with control group. It was also noted that the numbers of both CD4+ and CD8+ T cells in Taxol-treated tumours were lower than those in the tumours treated with carrier alone (Fig. 6a). Delivery of PTX via PEG2k-Fmoc-NLG(L) was associated with a similar reduction in the numbers of CD4+ and CD8+ T cells (Fig. 6a).